Message from the CEO
In just a decade, Samsung Biologics has rapidly evolved into the world’s largest and best-in-class CDMO service partner. We continue to expand our business scope to make the next leap in biopharma, and in this next decade, we will continue to build greater capabilities to meet new market demand as a top service innovator in the biopharmaceutical industry while ensuring quality and stable supply of life-saving drugs.
Since its launch, Samsung Biologics has not only expanded its manufacturing capacity but also established a solid track record of successful regulatory approvals and award-winning client satisfaction. In efforts to provide the highest level of customer-centric services, Samsung Biologics has implemented leading edge technologies and with great agility, demonstrated distinguished processes in terms of speed, price competitiveness, quality, and efficiency.
We are facing a time of significant challenges and market dynamics. To respond, we made bold moves by adding Plant 4 to the current site and purchasing additional land for Bio Campus II, as well as initiating our global expansion plan through the opening of our CDO R&D Center in San Francisco. We expect synergies from collaborations between the new global locations and our manufacturing sites in Songdo.
We embrace responsibility, expertise, and pride in our work, and will continue on our noble mission to enable improved accessibility of biomedicines and consequently the quality of life for people around the globe. We will challenge ourselves to improve in all facets of our business through innovation, dedication, and excellence so that we can continue to add meaningful value to all of our clients, partners, and shareholders.
Thank you for your continuous trust and support.
